CVC  Cato BioVentures

     Office Locations:

4364 South Alston Avenue
Durham, NC 27713
Phone: 919-361-2286
Fax: 919-361-2290



  • Early
  • Expansion
  • Growth
  • Middle Market



  • Life Sciences & Healthcare
  • Medical Device



    Cato BioVentures is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization (CRO). For over 25 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of sucessful product development programs. The firm focuses on early to mid-stage investment opportunities in private companies and undervalued public companies. Through strategic CRO service agreements with Cato Research, the firm has invested its 'CRO Service Capital' in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity. Cato focuses on high value life science investment opportunities at all stages of development and across multiple therapeutic and technical areas. The firm is uniquely interested in product development opportunities in undervalued public companies that have gone off track or fallen out of favor with the investment community for technical reasons.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Allen Cato MD, PhD Principal
    Daniel Pharand CA, CPA Principal
    Jo Cato PhD Vice President
    Lynda Sutton BS Principal
    Michael Cato MS, RAC Vice President


    Portfolio companies include:

        web link

      Advanced Pain Remedies
        web link

        web link

        web link

        web link

      Cancer Advances
        web link

        web link

        web link

        web link

      Cumberland Pharmaceuticals
        web link

        web link

      Echo Therapeutics
        web link

      Emmaus Medical
        web link

        web link

        web link

        web link

        web link

        web link

        web link

        web link

      Neuren Pharmaceuticals
        web link

        web link

        web link

        web link


    Recent News: